RE:RE:Observations on valuation factorsHi GV. Thanks for the perspectives.
I guess my assumption is that if biotech overall is hot and rvx-208 (apabetalone) is in phase lll BETonMACE that investors in biotechs would take notice. Of course Resverlogix and rvx-208 (apabetalone) have low awareness and credibility with USA investors because it is not on a high profile, credible exchange like NASDAQ.
My guess is that rvx-208 (apabetalone) and RVX have higher visibility within the scientific community but that will not drive the share price until a BP, regional player or fund thinks it is a promising drug.
I agree with you re Zenith needing a separate board and/or a new CEO (hopefully with a very high track record with one of the big boys).
I guess the only thing we know is that they are working on epigenetic drugs directed at hematological tumours and solid tumours. We know their focus is on unmet needs and this at least provides the potential for early trials. We also know that Zenith is not starting at ground zero with regarding epigenetic drug development. In addition they will have received direct scientific knowledge from the post hoc learning from rvx-208. This may allow them to leap-frog on their learning curve. We know that their drug development is no longer just a guess. They now build drugs by design.
I have not seen any evidence of IPO activity such as doing a road show to investors.
That being said I guess only the scientists and management know what they have.
So I guess there will not be any money to be made soon. I'm high on the science and remain long.
GLTA DYODD
Toinv